Enabling portable delivery of large-molecule biologics to the lungs

Purpose and goal

The purpose of the project is enable pulmonary delivery of large molecule biologic drugs using portable inhalers. Here we aim to demonstrate sucessful in-vivo pulmonary delivery and expression in lung of mRNA therapeutics in a relevant model system using a new spray nozzle technology.

Expected effects and result

We expect to be able to demonstrate uptake of mRNA in lung tissue in living model systems after administration with our new spray nozzle. This would represent an important milestone and enable us to move forward in the commercial process, to form the team and a company, develop the business strategy, and approach potential partners and customers.

Planned approach and implementation

We have already fabricated and tested the Swirl spray nozzles in in-vitro systems. We have demonstrated that sprays does not damage sensitive proteins, LNP or EVs; and we have demonstrated successful delivery of mRNA to cell cultures. We now plan to show proof-of-concept in an appropriate model system. This is a key step taking the technology from its current prototype stage where experimental models have been developed to get first proof-of-concept in vivo. We have planned this work together with Karolinska Institutet Huddinge.